Literature DB >> 7998491

Platelet-activating factor (PAF) and the development of chronic subdural haematoma.

Y Hirasima1, S Endo, R Kato, T Ohmori, T Nagahori, M Nishijima, K Karasawa, S Nojima, A Takaku.   

Abstract

Platelet activating factor (PAF) content and PAF-acetylhydrolase (PAFAH) activity were measured in the plasma and haematoma of 34 chronic subdural haematoma (CSH) patients. The plasma PAF level in patients with CSH was higher than that in healthy controls. Although there was no correlation between the plasma PAF levels and the interval between the onset of symptoms and the day of sampling, namely, the interval after bleeding, the haematoma PAF level gradually decreased according to the interval after the onset of symptoms. There was no difference between plasma PAFAH activity in patients with CSH and that in healthy controls, and haematoma enzyme activity gradually increased correlated with the interval between the onset of symptoms and surgery. In addition, the localization of PAF in haematoma capsules was histochemically determined. PAF was solely localized to the peri-sinusoidal vessels in the outer membrane of haematoma capsules. Based on these biochemical and histochemical studies, we speculated that PAF may play a role in the development of chronic subdural haematomas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7998491     DOI: 10.1007/BF01400868

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  25 in total

1.  Antibodies to synthetic platelet-activating factor (1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine) analogues with substituents at the sn-2 position.

Authors:  K Karasawa; N Satoh; M Masuda; M Setaka; K Hashimoto; K Ishibashi; S Nojima
Journal:  J Biochem       Date:  1991-11       Impact factor: 3.387

2.  Paf-acether (platelet-activating factor) increases microvascular permeability and affects endothelium-granulocyte interaction in microvascular beds.

Authors:  J Björk; L Lindbom; B Gerdin; G Smedegård; K E Arfors; J Benveniste
Journal:  Acta Physiol Scand       Date:  1983-11

3.  Effects of platelet activating factor on the chemotaxis of normodense eosinophils from normal subjects.

Authors:  N Tamura; D K Agrawal; F A Suliaman; R G Townley
Journal:  Biochem Biophys Res Commun       Date:  1987-02-13       Impact factor: 3.575

4.  Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils.

Authors:  A J Wardlaw; R Moqbel; O Cromwell; A B Kay
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

5.  Increased biosynthesis of platelet-activating factor in activated human eosinophils.

Authors:  T Lee; D J Lenihan; B Malone; L L Roddy; S I Wasserman
Journal:  J Biol Chem       Date:  1984-05-10       Impact factor: 5.157

6.  Inactivation of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by a plasma acetylhydrolase: higher activities in hypertensive rats.

Authors:  M L Blank; M N Hall; E A Cress; F Snyder
Journal:  Biochem Biophys Res Commun       Date:  1983-06-15       Impact factor: 3.575

7.  Platelet-activating factor (PAF) concentration and PAF acetylhydrolase activity in cerebrospinal fluid of patients with subarachnoid hemorrhage.

Authors:  Y Hirashima; S Endo; T Ohmori; R Kato; A Takaku
Journal:  J Neurosurg       Date:  1994-01       Impact factor: 5.115

8.  Immunofluorescent localization of platelet-activating factor (PAF) in the rat.

Authors:  Y Hirashima; R Kato; S Endo; A Takaku; K Karasawa; S Nojima
Journal:  Histochem J       Date:  1993-11

9.  Detection of platelet-activating factor in exudates of rats with phorbol myristate acetate-induced pleurisy.

Authors:  M Hayashi; J Kimura; K Yamaki; Y Suwabe; M Dozen; Y Imai; S Oh-ishi
Journal:  Thromb Res       Date:  1987-11-01       Impact factor: 3.944

10.  Oxygen radicals are not a prerequisite for neutrophil-mediated increased vascular permeability.

Authors:  S Rosengren; J Björk; G Smedegård
Journal:  Lab Invest       Date:  1988-05       Impact factor: 5.662

View more
  4 in total

1.  Local and systemic pro-inflammatory and anti-inflammatory cytokine patterns in patients with chronic subdural hematoma: a prospective study.

Authors:  Milo Stanisic; Ansgar Oddne Aasen; Are Hugo Pripp; Karl-Fredrik Lindegaard; Jon Ramm-Pettersen; Staale Petter Lyngstadaas; Jugoslav Ivanovic; Ane Konglund; Eivind Ilstad; Tiril Sandell; Omar Ellingsen; Terje Sæhle
Journal:  Inflamm Res       Date:  2012-04-19       Impact factor: 4.575

2.  Platelet-activating factor (PAF) and the formation of chronic subdural haematoma. Measurement of plasma PAF levels and anti-PAF immunoglobulin titers.

Authors:  Y Hirashima; S Endo; N Hayashi; K Karasawa; S Nojima; A Takaku
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

3.  Local elevation of the anti-inflammatory interleukin-10 in the pathogenesis of chronic subdural hematoma.

Authors:  Tsukasa Wada; Kiyoshi Kuroda; Yuki Yoshida; Kuniaki Ogasawara; Akira Ogawa; Shigeatsu Endo
Journal:  Neurosurg Rev       Date:  2006-03-10       Impact factor: 3.042

4.  Tranexamic Acid in Chronic Subdural Hematomas (TRACS): study protocol for a randomized controlled trial.

Authors:  Christian Iorio-Morin; Jocelyn Blanchard; Maxime Richer; David Mathieu
Journal:  Trials       Date:  2016-05-05       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.